References

1. Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcostegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007; 85 (5): 486-494.

2. Zuluaga MF, Mailhos C, Robinson G, Shima DT, Gurny R, Lange N. Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48 (4): 1767-1772.

3. Markabi S. Combination therapy from the regulatory perspective. Retina 2009; 29 (6 Suppl): S12-S14.

4. Karel I. Moznosti a ekonomické ukazatele lécby exsudativní vekem podmínené makulární degenerace s choroidální neovaskulární membránou. Cesk Slov Oftalmol 2007; 63 (5): 311-319.

5. Smiddy WE. Relative cost of a line of vision in age-related macular degeneration. Ophthalmology 2007; 114 (5): 847-854.

6. Smiddy WE. Economic implications of current age-related macular degeneration treatments. Ophthalmology 2009; 116 (3): 481-487.

7. Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010; 94 (2): 174-179.

8. Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S, Hori S.Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema.Ophthalmology. 2005 May;112(5):806-16.

9. Augustin AJ, Offermann I. Gibt es eine medikamentöse Therapie der altersbedingten Makuladegeneration?--Derzeitiger Stand und neue therapeutische Ansätze. Klin Monbl Augenheilkd 2008; 225 (6): 555-563.

10. Martin DF, Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology. 2012;119(7):1388-1398.

11. Silva R, Axer-Siegel R, Eldem B, et al; SECURE Study Group. The SECURE Study: Long-Term Safety of Ranibizumab 0.5 mg in Neovascular Age-related Macular Degeneration. Ophthalmology. 2013;120(1):130-139.

12. Singer MA, Awh CC, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175 1183.

13. Bhisitkul RB, Rofaghaet et al. Year 7 outcomes for ranibizumab-treated subjects in ANCHOR/MARINA: a multicenter, prospective cohort study. Paper presented at: Association for Research in Vision and Ophthalmology Annual Meeting; May 8, 2012; Fort Lauderdale,FL.

14. Gerhardt H, Golding M,  et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia J Cell Biol. 2003. 2003 Jun 23;161(6):1163-77

15. Frederick De Smet, I Segura et al: Mechanisms of Vessel Branching Filopodia on Endothelial Tip Cells Lead the Way Arteriosclerosis, Thrombosis, and Vascular Biology 2009;29:639-649.

16. Larrivée BFreitas CSuchting SBrunet IEichmann A.: Guidance of vascular development: lessons from the nervous system. Circ Res. 2009 Feb 27;104(4):428-41.

17. Butler JM, Guthrie SM, Koc M, Afzal A, Caballero S, Brooks HL, Mames RN, Segal MS, Grant MB, Scott EW.SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest. 2005 Jan;115(1):86-93.

18. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol 2001; 29 (3): 188-192.

19. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005; 46 (4): 1440-1444.

20. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000; 84 (9): 1064-1067.

21.  Jo N, Mailhos C, Ju M, Cheung E, Nishijima K, Robinson GS, Adamis AP, and Shima DT. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol (2006); 168(6):2036-2053.

22. Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor. Nat Rev Neurosci 2003; 4 (8): 628-636.

23. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med 2003; 9 (6): 244-250.

24. Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT.Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):767-73. Epub 2009 Feb 27.

25. Niemz MH. Laser-tissue interactions: Fundamentals and applications. 1st Edition. Berlin, Germany. Springer. 1996; 1-297 p.

26. Henriques J, Brito LX, Neves CM, Vaz FT. Laser tissue interactions. SPILM - Sociedade Portuguesa Interdisciplinar do Laser Médico. Handbook of Pos Graduate course in medical laser 1998; 1.

27.Schmidt-Erfurth U, Kiss C, Sacu S. The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies. Prog Retin Eye Res 2009; 28 (2): 145-154.

28. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431.

29. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355 (14): 1432-1444.

30. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908

31. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27:133-140.

32. Larsen MSchmidt-Erfurth et al. MONT BLANC Study Group.Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.Ophthalmology. 2012 May;119(5):992-1000.

33. 12-Months results  from Denali Study evaluating verteporfin PDT (Visudyne®) combination therapy QLT news release, June 15, 2010

34 .Koh ALee WK, et al. THE EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012 Sep;32(8):1453-64.

35.QLT ANNOUNCES FINAL RESULTS FROM ITS RADICAL STUDY EVALUATING VERTEPORFIN PDT (VISUDYNE®) COMBINATION THERAPY IN EXUDATIVE AMD Press Release, JUNE 22, 2010

36. Ranchod, Tushar M. MD; Ray, Subhransu K. MD, et al. LUCEDEX: A Prospective Study Comparing Ranibizumab plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Neovascular Age-Related Macular Degeneration. Retina. 2013 Mar30. 

37. ClinicalTrials.gov Identifier: NCT00390208

38.Combination Therapies for AMD: Latest Developments. P. Buchholz PhD. A. Buchholz.MD Janna Kirchhof PhD. Albert Augustin.MD

39. Sheidow T, Kertes PJ et al. The role of combination therapy in AMD: the Canadian study of Avastin and Vysudine in essudative AMD (CAVE STUDY), paper presented at Retina Congress 2009;sept 30-Oct. 4, 2009; New York, NY

40. A. Loewenstein, B. D. Kuppermann et al. Safety and Efficacy of OZURDEXTM (Dexamethasone Intravitreal Implant) as Adjunctive Therapy to Lucentis® in Patients With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). Invest Ophthalmol Vis Sci 2010;51

41. Flaxel CSchain MB, et al. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. Retina. 2012 Mar;32(3):417-23.

42. P Dugel P. Angiogenesis, Exudation, and Degeneration 2012 Meeting in Miami on Februay 4th. the 2-year results of the CABERNET study.

43. Söderberg AC; Algvere PV et al.Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospectiverandomised clinical study. Br J Ophthalmol.  2012; 96(5):714-8

44. Koch F, Scholtz S, Singh P, Koss MJ. Kombinierte intravitreale Therapie zur Behandlung der altersbedingten Makuladegeneration. Klin Monbl Augenheilkd 2008; 225 (12): 1003-1008.

45. Dugel PU. Anti-Platelet Derived Growth Factor: Where Do We Stand? Paper presented at: American Academy of Ophthalmology Annual Meeting; November 10, 2012; Chicago

46. Anti-PDGF Combination Therapy in Neovascular Age-related Macular Degeneration: Results of a Phase 2b Study By Pravin U. Dugel, MD RetinaToday March 2013.

47. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006; 9 (4): 225-230.

48. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99 (17): 11393-11398.

49.Two year results of phase 3 studies with EYLEA (aflibercept) injection in wet AMD show sustained improvement in visual acuity [press release]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc; December 5, 2011.

50.  Heier JS. VEGF Trap-Eye vs ranibizumab for neovascular AMD: results from 2457 patients in the phase 3 VIEW 1 and VIEW 2 studies. Paper presented at: Retina Society Annual Meeting; September 22-25; Rome, Italy.

51. Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol 2009; 247 (6): 767-773.

52. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P, Lutty GA. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 2006; 82 (1): 99-110.

53. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J, DiBartolomeo R, Wei LL. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006; 17 (2): 167-176.

54. Diago T, Pulido JS, Molina JR, Collett LC, Link TP, Ryan EH Jr. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 2008; 83 (2): 231-234.

55. Wilson HL, Schwartz DM, Bhatt HR, McCulloch CE, Duncan JL. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration. Am J Ophthalmol 2004; 137 (4): 615-624.

56. Fischer T. Az idoskori maculadegeneráció megelozésének és preventív terápiájának az újabb kórélettani és klinikai észlelésekre alapozott lehetséges stratégiája. [A new possible strategy for prevention and preventive treatment of age-related macular degeneration resting on recent clinical and pathophysiological observations]. Orv Hetil 2009; 150 (11): 503-512.

57. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, Kotlovker D, Chung CY, Kim RY; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124 (11): 1532-1542.

58. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145 (2): 239-248.

59. Lalwani GA, Fung AE, Michels S, Dubovy SR, Feuer WJ Jr., Puliafito CA, Rosenfeld PJ. An OCT-guided variable-dosing regimen with ranibizumab (Lucentis) in neovascular AMD: two year results of the PrONTO study. ARVO. Fort Lauderdale, USA, May 6-10, 2007. 2007; E-Abstract 1834-B694.

60. Cardillo JA, Melo LA Jr, Costa RA, Skaf M, Belfort R Jr, Souza-Filho AA, Farah ME, Kuppermann BD. Comparison of intravitreal versus posterior sub-Tenon’s capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 2005; 112 (9): 1557-1563.

61. Emerson MV, Lauer AK. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 2007; 21 (4): 245-257.

62. Kaiser PK. Strategies for inhibiting vascular endothelial growth factor. Retina 2009; 29 (6) Suppl: S15-S17.

63. Geltzer A, Turalba A, Vedula SS.Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005022.